CASI Pharmaceuticals (CASIF) Short term Debt (2024 - 2025)
CASI Pharmaceuticals (CASIF) reported Short term Debt of $19.2 million for Q4 2025, up 4.38% on a YoY basis from $18.4 million in Q4 2024, and up 4.38% quarter-over-quarter from $18.4 million in Q4 2024.
CASI Pharmaceuticals (CASIF) Short term Debt (2024 - 2025) Analysis & Trends
CASI Pharmaceuticals has reported Short term Debt for 2 years, with the latest figure at $19.2 million in Q4 2025.
- For the quarter ending Q4 2025, Short term Debt rose 4.38% year-over-year to $19.2 million; the trailing twelve-month figure through Dec 2025 stood at $19.2 million (up 4.38% YoY), and the FY2025 full-year result was $19.2 million, up 4.38% from the prior year.
- Short term Debt for Q4 2025 stood at $19.2 million, up from $18.4 million in the prior quarter.
- The five-year high for Short term Debt was $19.2 million in Q4 2025, with the low at $18.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 860,679.92 Bn | 860,679.89 Bn | - |
| 2 | Belite Bio | 55,284.00 Bn | 55,284.00 Bn | - |
| 3 | Quantum Biopharma | 16,206.94 Bn | 16,206.93 Bn | - |
| 4 | Legend Biotech | 3,318.00 Bn | 3,317.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,543.84 Bn | 1,543.84 Bn | - |
| 6 | Evaxion A | 1,449.11 Bn | 1,449.09 Bn | - |
| 7 | Psyence Biomedical | 216.99 Bn | 216.98 Bn | - |
| 8 | Vertex Pharmaceuticals | 115.22 Bn | 107.97 Bn | 2.59 Bn |
| 9 | Abivax | 90.58 Bn | 90.58 Bn | - |
| 10 | CASI Pharmaceuticals | - | - | 3.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 19.19 Mn |
| Dec 31, 2024 | 18.39 Mn |